- Details
- Robin Millman, a patient advocate, and 20+ year prostate cancer survivor shares a patient's perspective on the treatment landscape journey and hopes for the future of advanced prostate cancer treatment at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019. He highlights areas of interest and opportunity including general population screening and improved utilization of active surveilla...
|
- Details
- Charles Ryan presented the management of fatigue and cognitive changes induced by androgen deprivation therapy (ADT) at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). Dr. Ryan discusses the association between ADT and dementia, and also how combining ADT with abiraterone and prednisone can significantly improve fatigue in patients. Biographies: Charles J. Ryan, MD , the President...
|
- Details
- Neal Shore presents on the metabolic complications of androgen deprivation therapy and how to manage them at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). Biography: Neal Shore, MD , Medical Director for the Carolina Urologic Research Center, Myrtle Beach, South Carolina, USA. Related Content: APCCC 2019: Management of Metabolic Changes Download Presentation Slides Read the Full...
|
- Details
- Chris Parker presents on the utilization of antiresorptive therapy to reduce skeletal-related events (SRE) risk in men with bone metastatic castration-resistant prostate cancer (mCRPC) at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). Dr. Parker's presentation was part of a debate featured during the Bone and Bone Metastases Session. He summarized the evidence base in 2002 after t...
|
- Details
- Bertrand Tombal presented the use of antiresorptive therapy to reduce the risk of skeletal-related events (SRE) for the majority of men with castration-resistant prostate cancer (CRPC) and bone metastases. This presentation was part of the debate regarding how aggressive to be with bone-targeted therapy at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019 biennial meeting. Dr. Tombal'...
|
- Details
- Robert Reiter presented the definitions and concepts of oligometastatic prostate cancer at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). With improved imaging, this definition has become important from a terminology and treatment standpoint. Dr. Reiter highlights several potential pathways of oligometastasis from the primary tumor and highlights two important clinical questions r...
|
- Details
- Karim Fizazi presented on global access to treatment of advanced prostate cancer at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). He includes data on current access to radiotherapy on a worldwide level, the use of generic drugs, including docetaxel, abiraterone, and cabazitaxel expected to start in 2021. Lastly, he highlights the use of surgical castration vs. the use of LHRH ago...
|
- Details
- Mark Rubin presents on the future of metastatic prostate cancer in regards to biomarkers at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). He discusses both predictive and prognostic biomarkers, currently used biomarker tests, and a summary of some of the many studied biomarkers that are ready and appear promising. In conclusion he shares his beliefs of what we now require which a...
|
- Details
- In the last 10 years, there has been tremendous progress in the available treatment options for metastatic prostate cancer patients. In this presentation from William Oh at the 2019 Advanced Prostate Cancer Consensus Conference he highlights available treatment options for metastatic prostate cancer patients including serial systemic therapy with combinations of ADT with chemotherapy, abiraterone,...
|
- Details
- Kim Chi presented an update on the utilization of PARP inhibitors during the Management of Castration-Resistant Prostate Cancer (CRPC) session at the 2019 Advanced Prostate Cancer Consensus Conference (APCCC). Leading his presentation with the most recent positive phase III results from Lynparza® (olaparib), the only PARP inhibitor with positive phase III results in four different cancer types. He...
|
